Enterprise Value

1.20B

Cash

370.5M

Avg Qtr Burn

-16.33M

Short % of Float

10.03%

Insider Ownership

13.32%

Institutional Own.

86.68%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bitopertin (GlyT1 inhibitor) Details
erythropoietic porphyrias, X-linked protoporphyria

Big Mover™

Susp. Mover™

Phase 2

Data readout

Bitopertin (GlyT1 inhibitor) Details
Rare genetic disease, Anemia

Phase 1/2

Data readout

DISC-0974 Details
Myelofibrosis, Anemia, Chronic kidney disease

Phase 1/2

Data readout

DISC-3405 Details
Polycythemia vera

Phase 1

Data readout

Phase 1

Initiation

GEM103 Details
Age-related macular degeneration

Failed

Discontinued

GEM103 Details
Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued